-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that a 5.
1-category new drug named Safinamide Tablets has submitted a marketing application in China and was accepted
.
According to public information, safinamide, a new drug for the treatment of Parkinson's disease, has been approved by the US FDA in 2017, becoming the first new chemical entity approved in the United States for the treatment of Parkinson's disease in more than a decade
.
Publicly available data reveal that safinamide is a novel chemical entity with a unique mode of action involving selective and reversible monoamine oxidase B (MAO-B) inhibition and blockade of voltage-dependent sodium channels, thereby modulating aberrant glutamate acid release
.
The drug was developed by Newron Pharmaceuticals and commercialized by Zambon, Meiji Seika, Eisai, and Supernus Pharmaceuticals
.
The industry believes that the submission of a listing application for safinamide tablets in China means that it will soon come to China, thereby benefiting more Parkinson's disease patients
.
It is understood that Parkinson's disease, as a common neurodegenerative disease, clinical manifestations mainly include resting tremor, bradykinesia, rigidity and postural gait disturbance, and may be accompanied by non-motor symptoms such as depression, constipation and sleep disturbance.
Patients' quality of life and daily functioning are affected
.
According to incomplete statistics, there are about 10 million Parkinson's disease patients in the world
.
Based on the huge patient population and treatment demand, the global Parkinson's drug market will reach US$4.
564 billion in 2020, and is expected to increase to US$5.
934 billion at a CAGR of 4.
68% in 2026
.
In this context, the industry generally believes that with the background of a huge patient base and the deepening of global Lai Lihua, Parkinson's disease treatment drugs will have broader market prospects in the future, and more and more companies will enter the competition.
market
.
It is reported that many domestic pharmaceutical companies are accelerating their deployment in this field.
.
As earlier, Green Valley (Shanghai) Pharmaceutical Technology Co.
, Ltd.
disclosed that the company has received a written notice from the U.
S.
Food and Drug Administration (FDA) that it has approved "971" (English name: Sodium Oligomannate, code name: GV -971) to carry out an international multi-center Phase II clinical trial (IND159315) for the treatment of Parkinson's disease, and the approval will take effect from December 16, 2021
.
Last year, Luye Pharma announced that its rotigotine behenate extended-release microspheres for injection had been approved for clinical trials on October 21, 2021
.
The stable release of the drug in the human body can improve the motor and non-motor symptoms of patients with Parkinson's disease, reduce the "switch" phenomenon and the occurrence of motor complications in patients with advanced Parkinson's disease, and long-term application is expected to delay the occurrence of motor complications
.
In addition, Shenzhen Zhenluo Technology Co.
, Ltd.
also completed the B+ round of financing of RMB 100 million last year
.
It is reported that Zhenluo Science was established in 2013, taking Parkinson's disease as the entry point for the central nervous system disease market, and providing technical and service solutions for patients, clinical experts and pharmaceutical device companies
.
The funds from this round of financing will be used for Zhenluo scientific and technological research, product development, international scientific research cooperation and global business expansion
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
1-category new drug named Safinamide Tablets has submitted a marketing application in China and was accepted
.
According to public information, safinamide, a new drug for the treatment of Parkinson's disease, has been approved by the US FDA in 2017, becoming the first new chemical entity approved in the United States for the treatment of Parkinson's disease in more than a decade
.
Publicly available data reveal that safinamide is a novel chemical entity with a unique mode of action involving selective and reversible monoamine oxidase B (MAO-B) inhibition and blockade of voltage-dependent sodium channels, thereby modulating aberrant glutamate acid release
.
The drug was developed by Newron Pharmaceuticals and commercialized by Zambon, Meiji Seika, Eisai, and Supernus Pharmaceuticals
.
The industry believes that the submission of a listing application for safinamide tablets in China means that it will soon come to China, thereby benefiting more Parkinson's disease patients
.
It is understood that Parkinson's disease, as a common neurodegenerative disease, clinical manifestations mainly include resting tremor, bradykinesia, rigidity and postural gait disturbance, and may be accompanied by non-motor symptoms such as depression, constipation and sleep disturbance.
Patients' quality of life and daily functioning are affected
.
According to incomplete statistics, there are about 10 million Parkinson's disease patients in the world
.
Based on the huge patient population and treatment demand, the global Parkinson's drug market will reach US$4.
564 billion in 2020, and is expected to increase to US$5.
934 billion at a CAGR of 4.
68% in 2026
.
In this context, the industry generally believes that with the background of a huge patient base and the deepening of global Lai Lihua, Parkinson's disease treatment drugs will have broader market prospects in the future, and more and more companies will enter the competition.
market
.
It is reported that many domestic pharmaceutical companies are accelerating their deployment in this field.
.
As earlier, Green Valley (Shanghai) Pharmaceutical Technology Co.
, Ltd.
disclosed that the company has received a written notice from the U.
S.
Food and Drug Administration (FDA) that it has approved "971" (English name: Sodium Oligomannate, code name: GV -971) to carry out an international multi-center Phase II clinical trial (IND159315) for the treatment of Parkinson's disease, and the approval will take effect from December 16, 2021
.
Last year, Luye Pharma announced that its rotigotine behenate extended-release microspheres for injection had been approved for clinical trials on October 21, 2021
.
The stable release of the drug in the human body can improve the motor and non-motor symptoms of patients with Parkinson's disease, reduce the "switch" phenomenon and the occurrence of motor complications in patients with advanced Parkinson's disease, and long-term application is expected to delay the occurrence of motor complications
.
In addition, Shenzhen Zhenluo Technology Co.
, Ltd.
also completed the B+ round of financing of RMB 100 million last year
.
It is reported that Zhenluo Science was established in 2013, taking Parkinson's disease as the entry point for the central nervous system disease market, and providing technical and service solutions for patients, clinical experts and pharmaceutical device companies
.
The funds from this round of financing will be used for Zhenluo scientific and technological research, product development, international scientific research cooperation and global business expansion
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
